Electromed, Inc. Announces Clinical Abstract Poster at ATS Conference: Bronchiectasis Patients Showed Improved Outcomes and Reduction in Healthcare Resource Utilization When Using HFCWO Therapy

Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) released a report detailing findings from a third-party clinical study presented at the American Thoracic Society International Conference in San Francisco. The study demonstrated that patients using high frequency chest wall oscillation (HFCWO) therapy showed improved health outcomes and a reduction in healthcare resource utilization (HCRU), including lower medication usage. The analysis focused on non-cystic fibrosis bronchiectasis patients, emphasizing HFCWO's effectiveness in enhancing patient care and reducing hospitalizations.

Positive

• HFCWO therapy linked to improved health outcomes.
• Reduction in healthcare resource utilization, including medication usage.
• Significant findings supporting the effectiveness of the SmartVest system.

Negative

• None.

 

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (NYSE American: ELMD) today announced the results of a third-party, clinical study presented as a clinical abstract poster at the American Thoracic Society International Conference in San Francisco, CA. The study’s key findings reveal that patients who used high frequency chest wall oscillation (“HFCWO”) therapy experienced an improvement in health outcomes, as well as a reduction in healthcare resource utilization (“HCRU”), including a reduction in medication usage.

An independent retrospective cohort analysis was conducted on patients with non-cystic fibrosis bronchiectasis patients (“NCFBE”) who received HFCWO therapy using IQVIA’s PharMetrics Plus^® for MedTech, one of the largest US health plan databases of adjudicated integrated medical and pharmacy claims. The study aimed to understand patient characteristics and compare HCRU and outcomes (both before and after receipt of HFCWO) among NCFBE patients, in a large administrative claims database representative of the US commercially-insured population (including Medicare Advantage).

“We are pleased to further the body of evidence in support of HFCWO therapy and SmartVest, continuously showing improved patient outcomes, including a reduction in hospitalizations,” commented Kathleen Skarvan, President and Chief Executive Officer of Electromed. “These important findings further our mission and commitment to helping patients breathe easier and live better.”

Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi. The condition is associated with recurrent lower respiratory infections, inflammation, reduction in pulmonary function, impaired respiratory secretion clearance, increased hospitalizations and medication use, and increased morbidity and mortality.^1,2,3

The SmartVest system uses HFCWO, a clinically proven therapy that helps clear the lungs of excess secretions, thereby reducing the risk of respiratory infections and hospitalizations. HFCWO delivers alternating pulses of air into a vest garment that rapidly compresses and releases the chest wall, resulting in an oscillation in airflow within the airways that acts to loosen, thin, and propel mucus toward the major airways where it can be expectorated.

About Electromed, Inc.

Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest^® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about Electromed can be found at www.smartvest.com.

______________________

1 King PT et al. COPD. 2005;2(1):27-34.

2 Alzeer AH et al. BMC Pulm Med. 2007; 7:17.

3 Seitz AE et al. Chest. 2010;138(4):944-949.

EM00630.2022-05

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005013/en/

Kathleen Skarvan

President and Chief Executive Officer

kskarvan@electromed.com

952-758-9299

Source: Electromed, Inc.

FAQ

What were the key findings of the recent clinical study on ELMD's HFCWO therapy?

The study found that HFCWO therapy improved health outcomes and reduced healthcare resource utilization among patients.

When was the clinical study presented for Electromed, Inc.?

The clinical study was presented at the American Thoracic Society International Conference in San Francisco.

What is the stock symbol for Electromed, Inc.?

The stock symbol for Electromed, Inc. is ELMD.

How does HFCWO therapy benefit bronchiectasis patients?

HFCWO therapy helps clear lung secretions, reducing hospitalization risks and improving overall respiratory health.